Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
ULTIMATE-DAPT:急性冠狀動脈綜合症患者於經皮冠狀動脈介入術後第1至第12個月,單獨使用Ticagrelor對比Ticagrelor聯合阿司匹林:一項隨機、安慰劑對照、雙盲臨床試驗。
Lancet 2024-04-10
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.
糖尿病和動脈粥樣硬化患者使用 Ticagrelor 與阿司匹林的肢體結果。
J Am Coll Cardiol 2024-04-24
One- Versus Three-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease.
慢性腎臟疾病高出血風險患者中一個月對比三個月的雙抗血小板治療。
Am J Cardiol 2024-06-13
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.
急性冠狀動脈綜合症患者與非患者中,降級至 ticagrelor 單藥治療與 12 個月雙重抗血小板治療的比較:隨機試驗的系統性回顧及個別患者層級的 meta 分析。
Lancet 2024-09-03
Risk factors for major bleeding among patients with chronic kidney disease treated with acetylsalicylic acid.
慢性腎病患者使用 acetylsalicylic acid 的重大出血風險因素。
Kidney Blood Press Res 2024-11-11
Use of Aspirin and Initial Cardiovascular and Bleeding Risk in Patients with Chronic Kidney Disease.
慢性腎病患者中阿斯匹林的使用與初始心血管及出血風險。
Clin J Am Soc Nephrol 2025-03-14